Literature DB >> 26181090

Contraceptive Practices Among Female Cancer Survivors of Reproductive Age.

Sally A Dominick1, Mamie R McLean, Brian W Whitcomb, Jessica R Gorman, Jennifer E Mersereau, Janet M Bouknight, H Irene Su.   

Abstract

OBJECTIVE: To compare rates of contraception between reproductive-aged cancer survivors and women in the general U.S. POPULATION: Among survivors, the study examined factors associated with use of contraception and emergency contraception.
METHODS: This study analyzed enrollment data from an ongoing national prospective cohort study on reproductive health after cancer entitled the Fertility Information Research Study. We compared current contraceptive use in survivors with that of the general population ascertained by the 2006-2010 National Survey for Family Growth. Log-binomial regression models estimated relative risks for characteristics associated with use of contraception, World Health Organization tiers I-II (sterilization and hormonal) contraceptive methods, and emergency contraception in survivors.
RESULTS: Data from 295 survivors (mean age 31.6±5.7 years, range 20-44 years) enrolled in this prospective study (85% response rate) were examined. Age-adjusted rates of using tiers I-II contraceptive methods were lower in survivors than the general population (34% [28.8-40.0] compared with 53% [51.5-54.5], P<.01). Only 56% of survivors reported receiving family planning services (counseling, prescription or procedure related to birth control) since cancer diagnosis. In adjusted analysis, receipt of family planning services was associated with both increased use of tiers I-II contraceptive methods (relative risk 1.3, 95% confidence interval [CI] 1.1-1.5) and accessing emergency contraception (relative risk 5.0, 95% CI 1.6-16.3) in survivors.
CONCLUSION: Lower rates of using tiers I-II contraceptive methods were found in reproductive-aged cancer survivors compared with the general population of U.S. women. Exposure to family planning services across the cancer-care continuum may improve contraception use among these women. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01843140. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2015        PMID: 26181090      PMCID: PMC4545298          DOI: 10.1097/AOG.0000000000000963

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  18 in total

1.  Estimating the relative risk in cohort studies and clinical trials of common outcomes.

Authors:  Louise-Anne McNutt; Chuntao Wu; Xiaonan Xue; Jean Paul Hafner
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

2.  Factors associated with pregnancy attempts among female young adult cancer survivors.

Authors:  Sally A Dominick; Brian W Whitcomb; Jessica R Gorman; Jennifer E Mersereau; Karine Chung; H Irene Su
Journal:  J Cancer Surviv       Date:  2014-05-24       Impact factor: 4.442

3.  A Diversified Recruitment Approach Incorporating Social Media Leads to Research Participation Among Young Adult-Aged Female Cancer Survivors.

Authors:  Jessica R Gorman; Samantha C Roberts; Sally A Dominick; Vanessa L Malcarne; Andrew C Dietz; H Irene Su
Journal:  J Adolesc Young Adult Oncol       Date:  2014-06-01       Impact factor: 2.223

4.  Cancer and contraception. Release date May 2012. SFP Guideline #20121.

Authors:  Ashlesha Patel; E Bimla Schwarz
Journal:  Contraception       Date:  2012-06-07       Impact factor: 3.375

5.  Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995.

Authors:  Jo Jones; William Mosher; Kimberly Daniels
Journal:  Natl Health Stat Report       Date:  2012-10-18

6.  A qualitative study of the information needs of premenopausal women with breast cancer in terms of contraception, sexuality, early menopause, and fertility.

Authors:  Banu Karaöz; Hilmiye Aksu; Mert Küçük
Journal:  Int J Gynaecol Obstet       Date:  2010-02-11       Impact factor: 3.561

7.  Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk.

Authors:  Molly M Quinn; Joseph M Letourneau; Mitchell P Rosen
Journal:  Contraception       Date:  2014-01-28       Impact factor: 3.375

Review 8.  Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Charles A Sklar; John D Boice; John J Mulvihill; John A Whitton; Marilyn Stovall; Yutaka Yasui
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

9.  Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.

Authors:  H Irene Su; Mary D Sammel; Jamie Green; Luke Velders; Corrie Stankiewicz; Jennifer Matro; Ellen W Freeman; Clarisa R Gracia; Angela DeMichele
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

10.  A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study.

Authors:  John P Pierce; Susan Faerber; Fred A Wright; Cheryl L Rock; Vicky Newman; Shirley W Flatt; Sheila Kealey; Vicky E Jones; Bette J Caan; Ellen B Gold; Mary Haan; Kathryn A Hollenbach; Lovell Jones; James R Marshall; Cheryl Ritenbaugh; Marcia L Stefanick; Cynthia Thomson; Linda Wasserman; Loki Natarajan; Ronald G Thomas; Elizabeth A Gilpin
Journal:  Control Clin Trials       Date:  2002-12
View more
  15 in total

Review 1.  Fertility and pregnancy in cancer survivors.

Authors:  Monica Tang; Kate Webber
Journal:  Obstet Med       Date:  2018-03-29

Review 2.  Unintended Pregnancy: A Systematic Review of Contraception Use and Counseling in Women With Cancer.

Authors:  Laura Britton
Journal:  Clin J Oncol Nurs       Date:  2017-04-01       Impact factor: 1.027

3.  Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor.

Authors:  Tracy N Hadnott; Shaylyn S Stark; Alexa Medica; Andrew C Dietz; Maria Elena Martinez; Brian W Whitcomb; H Irene Su
Journal:  Fertil Steril       Date:  2019-04       Impact factor: 7.329

Review 4.  Best Practices in Counseling Young Female Cancer Survivors on Reproductive Health.

Authors:  Ksenya Shliakhtsitsava; Deepika Suresh; Tracy Hadnott; H Irene Su
Journal:  Semin Reprod Med       Date:  2017-10-16       Impact factor: 1.303

5.  Childbirth after adolescent and young adult cancer: a population-based study.

Authors:  Hazel B Nichols; Chelsea Anderson; Kathryn J Ruddy; Kristin Z Black; Barbara Luke; Stephanie M Engel; Jennifer E Mersereau
Journal:  J Cancer Surviv       Date:  2018-05-22       Impact factor: 4.442

Review 6.  Exogenous reproductive hormone use in breast cancer survivors and previvors.

Authors:  Ines Vaz-Luis; Ann H Partridge
Journal:  Nat Rev Clin Oncol       Date:  2018-01-23       Impact factor: 66.675

7.  Contraceptive utilization and counseling among breast cancer survivors.

Authors:  Sheila Krishnan Mody; Jessica R Gorman; Lisa P Oakley; Tracy Layton; Barbara A Parker; Danielle Panelli
Journal:  J Cancer Surviv       Date:  2019-05-08       Impact factor: 4.442

Review 8.  Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.

Authors:  Ksenya Shliakhtsitsava; Sally A D Romero; Samantha Rose Dewald; H Irene Su
Journal:  Leuk Lymphoma       Date:  2017-07-21

9.  Efficacy of a web-based women's health survivorship care plan for young breast cancer survivors: a randomized controlled trial.

Authors:  H Irene Su; Shaylyn Stark; Brian Kwan; Sarah Boles; Diana Chingos; Jennifer Ehren; Jessica R Gorman; Michael Krychman; Sally A D Romero; Jun J Mao; John P Pierce; Loki Natarajan
Journal:  Breast Cancer Res Treat       Date:  2019-05-03       Impact factor: 4.872

10.  Use of emergency contraception among female young adult cancer survivors.

Authors:  Alexa C O Medica; Shaylyn S Stark; Tracy N Hadnott; Andrew C Dietz; Sally A D Romero; Loki Natarajan; Elena Martinez; Brian W Whitcomb; H Irene Su
Journal:  Fertil Steril       Date:  2018-06       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.